SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

14 Apr 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update

30 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023

13 Mar 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023

06 Mar 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming Investor Conferences

28 Feb 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

22 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

14 Nov 2022 15:05:02 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

08 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

07 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present Data at IDWeek 2022

19 Oct 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

03 Oct 2022 07:05:00 By Nasdaq GlobeNewswire

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

22 Sep 2022 01:00:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

15 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming Investor Conference

07 Sep 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

06 Sep 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

10 Aug 2022 15:05:00 By Nasdaq GlobeNewswire